Drug Profile
Research programme: streptococcal A vaccine - Roche
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Roche
- Class Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Streptococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Streptococcal-infections in USA
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche
- 29 May 2007 Preclinical development is ongoing